AL
TVRD

ADE LLC’s Tvardi Therapeutics TVRD Stock Holding History

ADE LLC’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-17
Closed -$9K – 318
2020
Q4 		$9K Buy
+17
New +$8.91K 0.01% 270

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

ADE LLC's TVRD Position: Q1 2021 in Review

ADE LLC sold out of Tvardi Therapeutics (TVRD) in Q1 2021, closing a stake of 17 shares — an estimated $9K sold.

ADE LLC first reported a position in TVRD in Q4 2020 and held it in 1 quarter. The position peaked at $9K in Q4 2020. 167 funds tracked by Wall St. Rank hold TVRD as of Q1 2021.

  • ADE LLC reported no remaining Tvardi Therapeutics position as of Q1 2021 after selling out during the quarter.
  • ADE LLC sold 17 Tvardi Therapeutics shares in Q1 2021, an estimated $9K.
  • ADE LLC first reported a position in Tvardi Therapeutics in Q4 2020 and held it in 1 quarter.
  • ADE LLC's Tvardi Therapeutics position peaked at $9K in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2021.

Based on ADE LLC's 13F filing for Q1 2021, filed 16 Apr 2021.